A7i Intelligence Gulf Biotechnology Intelligence
Market

Science moving from discovery to impact

Follow the research, clinical programmes, technologies and intellectual property advancing biotechnology across the Gulf.

A four-arm robotic surgical system positioned over a training model in an operating theatre
A robotic surgical system at the Heart Centre of King Faisal Specialist Hospital and Research Centre, Riyadh, February 2025.Photo: Department for Science, Innovation and Technology, CC BY 2.0, cropped
Programmes at trial stage2Programmes at trial stage with published evidence.
Regulatory approvals tracked3Regulatory approvals recorded in the tracker.
Gulf-originated assets2Programmes where the underlying asset originates in the Gulf.

From discovery to global expansion

Where verified Gulf programmes sit along the path from research to export.

Programmes are shown at the furthest stage supported by publicly available evidence, and counts cover verified programmes. Choose a stage to filter the tracker, where emerging signals carry their own tag.

Data table
Verified programmes at each stage of translation
StageProgrammesGulf-originatedCollaborativeInternational asset adopted
Discovery11
Preclinical111
Clinical development2111
Regulatory approval333
Manufacturing111
Clinical adoption111
Global expansion66
Sources: A7i clinical and exports datasets Methodology

Clinical and Scientific Translation Tracker

Each programme at the furthest stage the evidence supports.

Data table
Clinical and scientific translation by stage
ProgrammeMarketStageStage dateOriginSource
Locally developed CAR-T for relapsed CD19-positive acute lymphoblastic leukaemiaKing Faisal Specialist Hospital and Research CentreSaudi ArabiaCell and gene therapyClinical trialAugust 2025Gulf-originatedSaudi Press Agency
APOE4-stratified Alzheimer's prevention trialIROS and Department of Health Abu Dhabi, with Halia TherapeuticsUAESmall moleculeClinical trialJune 2026International assetPharmaTimes
Gene therapy for spinal muscular atrophySidra Medicine, with NovartisQatarGene therapyClinical adoptionJuly 2026International assetHealthCare MEA
Structural genomic variant map of the Qatari populationSidra Medicine, with King's College LondonEmerging signal, verification in progressQatarPopulation genomicsDiscoveryJanuary 2026Gulf-originatedTracking
Emirati Genome Programme population analysisDepartment of Health Abu Dhabi and M42PreprintUAEPopulation genomicsDiscoverySeptember 2025Gulf-originatedmedRxiv (preprint)
ANKTIVA, bladder cancer and metastatic lung cancerSaudi Food and Drug Authority, with ImmunityBioSaudi ArabiaImmunotherapyApprovalFebruary 2026International assetImmunityBio investor relations
ESR1-targeted breast cancer therapyEmirates Drug Establishment, with AstraZenecaUAESmall moleculeApprovalJune 2026International assetThe National
Once-daily oral GLP-1 for weight managementEmirates Drug Establishment, with Eli LillyUAESmall moleculeApprovalApril 2026International assetHealthCare MEA
Insulin localisation programmeSaudiBio, with Novo Nordisk Saudi ArabiaRecorded at local manufacturing on the basis of a signed agreement and facility construction.Saudi ArabiaBiologicLocal manufacturingOctober 2024International assetLifera
Multi-cancer screening on population genomic dataAbu Dhabi Biobank, with BioTwinUAEDiagnosticPreclinicalJune 2026International assetGulf News
CRISPR therapy for sickle cell diseaseBahrain Oncology CentreEmerging signal, verification in progressBahrainGene editingClinical adoptionFebruary 2025International assetTracking
Sources: A7i clinical dataset Methodology

Regulatory Comparison Matrix

The six Gulf regulators, field by field.

Saudi Arabia

Verified 22 September 2026 · World Health Organization
Regulator
Saudi Food and Drug Authority
Pharmaceuticals authority
Saudi Food and Drug Authority
Medical device authority
Saudi Food and Drug Authority
IVD pathway
Medical Device Marketing Authorisation covering in-vitro diagnostics, with specific guidance for AI and big-data devices under MDS-G53
Local authorised representative
Required. A Saudi authorised representative holds the registration on the manufacturer's behalf; the certificate belongs to the manufacturer.
Reference-market recognition
Recognises approvals from founding GHTF jurisdictions
Centralised GCC route
Covers pharmaceuticals; devices and in-vitro diagnostics register nationally.
Clinical trial authority
Saudi Food and Drug Authority
Submission system
SFDA electronic systems
Published review timeline
Clinical trial approval reported as reduced from about 270 days to about 120 days.
Latest major change
Biosimilar guideline version 1.0 issued 10 June 2026, effective 10 July 2026.
Regulatory maturity
WHO Maturity Level 4 for medicines and vaccines, awarded 30 October 2023. Third regulatory authority worldwide and first in the Eastern Mediterranean to reach it.

UAE

Verified 22 September 2026 · Gulf News
Regulator
Emirates Drug Establishment
Pharmaceuticals authority
Emirates Drug Establishment, federally
Medical device authority
Emirates Drug Establishment, federally, with emirate-level facility licensing by DoH Abu Dhabi and the Dubai Health Authority
IVD pathway
Federal registration through the EDE; one certificate covers the country
Local authorised representative
Required. A UAE-based authorised representative acts as marketing authorisation holder.
Reference-market recognition
Recognises approvals from established reference markets
Centralised GCC route
Covers pharmaceuticals
Clinical trial authority
Ministry of Health and Prevention and emirate-level health authorities
Submission system
EDE electronic systems
Latest major change
Federal Decree-Law No. 38 of 2024 created the EDE, which assumed product registration from the Ministry of Health and Prevention.

Qatar

Verified 22 September 2026
Regulator
Ministry of Public Health
Pharmaceuticals authority
Ministry of Public Health, Pharmacy and Drug Control Department
Medical device authority
Ministry of Public Health
IVD pathway
National registration through the Ministry of Public Health
Local authorised representative
Required. Foreign manufacturers appoint a locally registered Qatari authorised representative to submit and hold registrations.
Reference-market recognition
Devices generally require prior authorisation from a founding GHTF jurisdiction: the United States, European Union, Canada, Australia, Japan or Saudi Arabia.
Centralised GCC route
Covers pharmaceuticals
Clinical trial authority
Ministry of Public Health
Submission system
Ministry electronic submission system

Bahrain

Verified 22 September 2026 · Kingdom of Bahrain national portal
Regulator
National Health Regulatory Authority
Pharmaceuticals authority
National Health Regulatory Authority
Medical device authority
National Health Regulatory Authority
IVD pathway
National registration under the NHRA device framework
Local authorised representative
Required. Filing is through a registered authorised representative.
Reference-market recognition
Recognises reference-market approvals
Centralised GCC route
Covers pharmaceuticals
Clinical trial authority
National Health Regulatory Authority
Submission system
NHRA electronic registration

Kuwait

Verified 22 September 2026
Regulator
Ministry of Health
Pharmaceuticals authority
Ministry of Health
Medical device authority
Ministry of Health, Medicine and Medical Products Registration and Regulatory Administration
IVD pathway
National registration through the Ministry of Health
Local authorised representative
Required
Reference-market recognition
Reference-led
Centralised GCC route
Covers pharmaceuticals
Clinical trial authority
Ministry of Health
Latest major change
Ministerial Decree No. 13 of 2022 governs device regulation

Oman

Verified 22 September 2026 · Lexis Middle East
Regulator
Ministry of Health
Pharmaceuticals authority
Ministry of Health
Medical device authority
Ministry of Health
IVD pathway
National registration through the Ministry of Health device portal
Local authorised representative
Required
Reference-market recognition
Recognises approvals from Saudi Arabia, the United States, European Union, Canada, Australia and Japan
Centralised GCC route
Covers pharmaceuticals
Clinical trial authority
Ministry of Health
Submission system
Ministry of Health device e-portal
Latest major change
A compliance deadline of six months from 22 April 2026 was reported for all imported medical devices, after which non-compliant shipments are suspended at entry points.

Regulatory information is provided for editorial and research purposes and should be verified directly with the relevant authority.

Data table
Regulatory comparison across the six GCC markets
FieldSaudi ArabiaUAEQatarBahrainKuwaitOman
RegulatorSaudi Food and Drug AuthorityEmirates Drug EstablishmentMinistry of Public HealthNational Health Regulatory AuthorityMinistry of HealthMinistry of Health
Pharmaceuticals authoritySaudi Food and Drug AuthorityEmirates Drug Establishment, federallyMinistry of Public Health, Pharmacy and Drug Control DepartmentNational Health Regulatory AuthorityMinistry of HealthMinistry of Health
Medical device authoritySaudi Food and Drug AuthorityEmirates Drug Establishment, federally, with emirate-level facility licensing by DoH Abu Dhabi and the Dubai Health AuthorityMinistry of Public HealthNational Health Regulatory AuthorityMinistry of Health, Medicine and Medical Products Registration and Regulatory AdministrationMinistry of Health
IVD pathwayMedical Device Marketing Authorisation covering in-vitro diagnostics, with specific guidance for AI and big-data devices under MDS-G53Federal registration through the EDE; one certificate covers the countryNational registration through the Ministry of Public HealthNational registration under the NHRA device frameworkNational registration through the Ministry of HealthNational registration through the Ministry of Health device portal
Local authorised representativeRequired. A Saudi authorised representative holds the registration on the manufacturer's behalf; the certificate belongs to the manufacturer.Required. A UAE-based authorised representative acts as marketing authorisation holder.Required. Foreign manufacturers appoint a locally registered Qatari authorised representative to submit and hold registrations.Required. Filing is through a registered authorised representative.RequiredRequired
Reference-market recognitionRecognises approvals from founding GHTF jurisdictionsRecognises approvals from established reference marketsDevices generally require prior authorisation from a founding GHTF jurisdiction: the United States, European Union, Canada, Australia, Japan or Saudi Arabia.Recognises reference-market approvalsReference-ledRecognises approvals from Saudi Arabia, the United States, European Union, Canada, Australia and Japan
Centralised GCC routeCovers pharmaceuticals; devices and in-vitro diagnostics register nationally.Covers pharmaceuticalsCovers pharmaceuticalsCovers pharmaceuticalsCovers pharmaceuticalsCovers pharmaceuticals
Clinical trial authoritySaudi Food and Drug AuthorityMinistry of Health and Prevention and emirate-level health authoritiesMinistry of Public HealthNational Health Regulatory AuthorityMinistry of HealthMinistry of Health
Submission systemSFDA electronic systemsEDE electronic systemsMinistry electronic submission systemNHRA electronic registrationMinistry of Health device e-portal
Published review timelineClinical trial approval reported as reduced from about 270 days to about 120 days.
Latest major changeBiosimilar guideline version 1.0 issued 10 June 2026, effective 10 July 2026.Federal Decree-Law No. 38 of 2024 created the EDE, which assumed product registration from the Ministry of Health and Prevention.Ministerial Decree No. 13 of 2022 governs device regulationA compliance deadline of six months from 22 April 2026 was reported for all imported medical devices, after which non-compliant shipments are suspended at entry points.
Regulatory maturityWHO Maturity Level 4 for medicines and vaccines, awarded 30 October 2023. Third regulatory authority worldwide and first in the Eastern Mediterranean to reach it.
SourceWorld Health OrganizationGulf NewsTrackingKingdom of Bahrain national portalTrackingLexis Middle East
Last verified22 September 202622 September 202622 September 202622 September 202622 September 202622 September 2026
Sources: Individually sourced in the table Methodology

The Wire, by email

Biotechnology, diagnostics, capital, regulation, science and manufacturing across the six Gulf markets. Every item is selected for its significance and carries a direct source and a verification date.